MAM
ALNY icon

Marquette Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Marquette Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81K Hold
6
– – ﹤0.01% 634
2026
Q1 		$1.99K Buy
+6
New +$2.04K ﹤0.01% 547
2025
Q4 		– Sell
-14
Closed -$6.38K – 709
2025
Q3 		$6.38K Buy
+14
New +$5.7K ﹤0.01% 290

Other funds holding ALNY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Marquette Asset Management's ALNY Position: Q2 2026 in Review

Marquette Asset Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 6 shares worth $1.81K. The position accounts for ﹤0.01% of the portfolio, ranked #634.

Marquette Asset Management first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.38K in Q3 2025. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Marquette Asset Management held 6 shares of Alnylam Pharmaceuticals worth $1.81K as of Q2 2026.
  • Marquette Asset Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #634 holding.
  • Marquette Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Marquette Asset Management's Alnylam Pharmaceuticals position peaked at $6.38K in Q3 2025.
  • 365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.